ISCT in the News

The Ethical and Legal Challenges in Unapproved Drug Access: A Talk with Patti Zettler

Sep 13, 2023

Imagine being given a shot at a cure before it's even approved. That's the fascinating world of expanded access programs for unapproved investigational interventions that we're exploring today with our esteemed guest, Patti Zettler, law professor and chair of the International Society for Cell and Gene Therapies Expanded Access Working Group. 

Navigating Expanded Access for Experimental Cell & Gene Therapies

Aug 9, 2023 | By Laertis Ikonomou

The field of cell and gene therapies (CGTs) is in steady growth. Tens of CGT products have received marketing authorization in various countries and regions, such as the European Union, the United States, Japan, South Korea, and Australia, and hundreds of clinical trials in the CGT sector are currently underway.

Overcoming Roadblocks: Innovations And Collaborations In Cell and Gene Therapy

Aug 2, 2023 | By Fenwick Eckhardt

Bad actors, lack of funding and skilled workforce shortages threaten to hinder the growth of cell and gene therapies. To unleash the transformative power of cell and gene therapies requires the concerted effort of the entire CGT community.

ISCT Annual Meeting: Industry Agrees to Act on Unproven Cell and Gene Therapies

Jun 16, 2023 | By Guy Martin

The potential for cell and gene therapy to save and transform lives is becoming more and more evident, a point observed by Bambi Grilley, chief regulatory officer of the International Society for Cell and Gene Therapy (ISCT), after attending its annual meeting in Paris this month.

ISCT 2023: Conference Highlights

Jun 8, 2023 | By Jasmine Hagan and Megan Giboney

The 2023 Annual Meeting of The International Society for Cell and Gene Therapy (ISCT; 31 May-3 June; Paris, France) brought together experts from every segment of the cell and gene therapy space, including academia, regulation and manufacturing, to explore and address the most critical issues in the field.

ISCT 2023: Editor's Picks

May 29, 2023 | By Jasmine Hagan and Megan Giboney

The International Society for Cell and Gene Therapy (ISCT) returns for its 29th annual meeting (31 May-3 June, Paris, France) with the theme, ‘celebrating the progress of advanced therapies and building the future through translation.’

ISCT 2023: ISCT: A Pre-Conference Interview with Jacques Galipeau

May 26, 2023

In advance of the International Society for Cell and Gene Therapy 2023 annual meeting (ISCT; 31 May-3 June; Paris, France), we spoke with Jacques Galipeau about what we can look forward to, how ISCT has expanded their roundtable plans from last year, and the developments that we can expect to see from the ISCT in the next year.

Inside The ISCT Global Regulators Summit 2023

May 30, 2023 | By Erin Harris

The ISCT Global Regulators Summit occurred in Paris on May 30, 2023, and brought together representatives of international regulatory agencies and government organizations to jointly address and better understand the global issue of the use of unproven cell and gene products.

By convening regulators from all major government agencies in North America, Europe, Asia, Australia and South and Central America, the objective was to facilitate knowledge sharing, discussion, and connections with like-minded agencies to help pave the path forward to protect patients from the use of unproven cell and gene products and the integrity of this fast-growing industry.

Policy Needed to Guide Expanded Access Programs in Cell and Gene Therapy, Experts Say

May 12, 2023 | By Catherine Shaffer

The International Society for Cell and Gene Therapy (ISCT) wants stakeholders in the field to consider concerns about scientific integrity, ethics, and equity in giving patients compassionate-use access to promising investigational treatments as more enter clinical trials.

Power List Perspectives: Challenges Facing Cell and Gene Therapy

May 12, 2023 | By Jamie Irvine

Cell and gene therapies are an increasingly proven therapeutic frontier – and look set to playing a pivotal role in the future of personalized and precision medicine. To date, more than 25 cell and gene therapies are licensed for use in the US alone, but – as with any evolving innovative approach – researchers and developers face multidimensional hurdles on the road to approval.

The Promise and Evolution of Cell and Gene Therapies for Rare Diseases

February 28, 2023 | By Jacques Galipeau, MD and Jaap Jan Boelens, MD, PhD

Cell and gene therapies — which encompass cell transplants — and genetic modifications and gene-editing of cells represent a significant paradigm shift in the treatment of rare diseases due to their unprecedented effectiveness and curative potential. 

2023 Market Outlook With AdBio and ISCT's Miguel Forte

February 2, 2023 | By Applied Biosystems by Thermo Fisher Scientific, qPCR

Miguel Forte is Entrepreneur in Residence at AdBio, a VC firm based in France, and President Elect of ISCT. Forte and Cell & Gene: The Podcast host, Erin Harris, break down market outlook perspective for the cell and gene therapy space. He provides valuable tips to employ when seeking VC partnership, and he covers ISCT's primary focus areas and what to expect from ISCT 2023 Paris.

Next Steps for MSC Innovation

January 18, 2023

David McCall, Commissioning Editor, BioInsights, talks to Jacques Galipeau, Associate Dean for Therapeutics Development at University of Wisconsin-Madison, and President of the International Society for Cell & Gene Therapy (ISCT)